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GenDrux: A biomedical literature search system
to identify gene expression-based drug sensitivity
in breast cancer
Chiquito Crasto1, Dajie Luo2, Feliciano Yu3, Andres Forero4 and Dongquan Chen4,5,6*

Abstract
Background: This paper describes the development of a web-based tool, GenDrux, which extracts and presents
(over the Internet) information related to the disease-gene-drug nexus. This information is archived from the
relevant biomedical literature using automated methods. GenDrux is designed to alleviate the difficulties of
manually processing the vast biomedical literature to identify disease-gene-drug relationships. GenDrux will evolve
with the literature without additional algorithmic modifications.
Results: GenDrux, a pilot system, is developed in the domain of breast cancer and can be accessed at http://www.
microarray.uab.edu/drug_gene.pl. GenDrux can be queried based on drug, gene and/or disease name. From over
8,000 relevant abstracts from the biomedical literature related to breast cancer, we have archived a corpus of more
than 4,000 articles that depict gene expression-drug activity relationships for breast cancer and related cancers. The
archiving process has been automated.
Conclusions: The successful development, implementation, and evaluation of this and similar systems when
created may provide clinicians with a tool for literature management, clinical decision making, thus setting the
platform for personalized therapy in the future.

Background
Cancer chemotherapy, gene expression, and drug
sensitivities

Typically, diagnoses for most diseases often result from
recognizing disease phenotypes, though these phenotypes might arise from a range of gene expression profiles [1]. Treatment modalities for cancer such as
chemotherapy can be personalized to the gene expression profile of a patient, if sensitivity of a pharmaceutical
product can be associated specific genes, treating the
underlying cause that stems from a patient’s specific
genotype. This is one of the means by which the eventual goals of personalized medicine, recognition of disease-gene relationships, gene-drug relationships [2], and
the disease-gene-drug nexus [3], may be achieved. Table
1 represents salient examples of an increasing number
of studies that have shown that recognizing gene-drug
and disease-gene relationships can be potentially useful
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to clinicians. A search in PubMed using the phrase
“breast cancer and drug” results in nearly 57,000
abstracts returned, of which nearly 10% are between
2009 and 2010. This is indicative of a greater emphasis
on increasing recent work on gene expression contributions to disease within the research and clinical communities. References to new discoveries of these
relationships are often available only in the non-annotated, free text of the biomedical literature. Manual
identification of this information is challenging. It
involves surveying thousands of articles to identify very
specific relationships. The resulting information has to
be processed, archived and efficaciously retrieved so that
it is available to clinicians and researchers.
Several drug-gene-disease relationship tools are currently available. PharmGKB[4,5] is a resource that provides information related to genotypes and phenotypes
in disease, disease related pathways as well as information related to pharmaceutical products. Lingpipe
(http://alias-i.com/lingpipe/index.html) is a resource that
allows open source access to natural language
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Table 1 Disease-Gene Expression-Drug Sensitivity Relationships in Breast Cancer
Disease

Gene

1

Breast
cancer

estrogen-induced genes

2

Breast
cancer

Her-2/ErbB2

3

NSCLC,
gastric

ERCC1, BRCA1

4

Breast
cancer

estrogen receptor, progesterone receptor, HER2, Ki-67,
p53, and bcl-2

5

Breast
cancer

Glutathione peroxidase

6

Breast
cancer

Aromatase Inhibitor, pS2

Drug

Sensitivity*

Estrogen

increase

Ref.
[8]

Tamoxifen

decrease

[9]

Cisplatin, docetaxel

Decrease

Doxorubicin, docetaxel,
tamoxifen

decrease (estrogen R, Kip67),
increase (Bcl2)

DHA, doxorubicin

increase

[12]

Letrozole

increase

[13]

[10,11]

Decrease suggests that increased expression of the mentioned gene decreases the drug sensitivity, or makes the drug more resistant.

processing algorithms, one of which is named entity
recognition (NER). Although it uses LingMed that
enables extraction of Medline literature similarly as the
GenDrux, described here, its target audience is not clinicians. Additionally, BANNER and ABNER are systems
that use NER to identify gene and protein names to
identify protein-protein interactions. BANNER[6] has to
be downloaded and installed. ABNER [7] is an open
source tool for automatically tagging genes, proteins,
and other entity names in text.
These sophisticated systems are subject to issues of
precision and recall if the entity is incorrectly identified.
Systems such as PharmGKB are manually curated and
its sources are myriad. Such resources are also comprehensive and not likely to be immediately useful to specialized clinicians. Additionally, while these systems are
free and open source, they have to be downloaded and
installed on the users’ computer. A browser based
search and retrieval system that is platform independent
and requires only a browser would likely be preferable.

Implementation
The objective was to create a Web-based literature
archiving and retrieval system that could be used by
clinicians and researchers to search for abstracts that
depicted research that identified drug-gene relationships.
Our basic methodology consists of two steps; 1) automated creation of the archive of the relevant biomedical
literature; and 2) creating the web-based query tool for
retrieval of information in response to users’ queries.
There is no client software to install.

Maintenance and update

E-Search

In GenDrux the drug names as well as the gene names
are extracted together with article PubMed IDs, article
titles and abstracts, from resources that are validated
repositories of this information and therefore not subject to uncertainties or ambiguities. GenDrux, in its current state, and when fully evolved, depending on how
quickly gene expression data and pharmaceutical product development keep up, will ensure accuracy of
information retrieved. GenDrux, is currently applied to
breast cancer, but is easily extensible to other diseases.
The tool can be accessed over the Internet through a
Web browser. The system is queried by means of a simple form. GenDrux has been tested for all the available
browsers in different computer platforms. This system
lends itself well to use by physicians and researchers.

Here parameters that are used to design a PubMed
search can be embedded in a universal resource locator
(URL). These parameters (of many possible parameters)
include search phrases (depicting the domain of
research, e.g., a disease, in this case “breast cancer”), a
range of dates, the journal, one or more authors, and
the maximum number of hits (in our case, 500, which is
the maximum allowed) returned. For example, our esearch URL was as follows: http://eutils.ncbi.nlm.nih.
gov/entrez/eutils/esearch.fcgi?db=pubmed&term="breast
+cancer+genes+drug"&minddate=0&maxdate=$date[1]
&retmax=500.
Since our aim is to identify pharmaceutical products
that might be related to specific genes implicated in
breast cancer, our search phrases consisted of “breast

Archiving the biomedical literature

To archive relevant literature in the domain of breast
cancer, we leveraged two tools (E-Search and E-Fetch),
from the E-utils suite, developed at the National Library
of Medicine (NLM). E-utility allows the extraction of
abstracts from PubMed in an automated fashion. We
developed a “wrapper"–a PERL (Practical Extraction and
Report Language) program that incorporated e-utils’
features.
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+cancer+gene+drug.” The “+” sign is used as an “AND”
during the search. In order to ensure that we could
extract as many abstracts as possible, our algorithm
looped over 500 abstracts retrieved per search for specific time periods starting from 1975 to the present. In
determining how many results would adequately represent the entire corpus of relevant literature, from 1975
to 1985 we searched twice a year, up to 1995, four
times a year and from then on, monthly. E-utils results
are retrieved as XML (eXtensible Markup Language)
files. We developed a PERL based XML parser that processed the E-Search results file. This results file consists
of a list of unique (and dynamically created) identifiers.
Each identifier represents a publication stored in
PubMed and can be “fetched” as an abstract.

The archive file was further filtered to restrict the
abstracts that contained gene information in the domain
of breast cancer, which also include names of drug
names. For this, we enlisted a comprehensive list of
names of pharmaceutical products using a database
from the Food and Drug Administration (FDA), the
National Cancer Institute (NCI) and the International
Classification of Diseases (ICD) web resources. The final
archive file contained articles that only referenced specific genes (by their names and aliases) and drugs.

E-Fetch

The results from E-search were further processed to
automatically download the abstracts. For each identifier
we developed another PERL “wrapper” that incorporated
the e-fetch URL. In the following example of the e-fetch
URL: “http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.
fcgi?db=pubmed&id="Unique_identifier"&rettype=abstract&retmode=XML”, the program fetches information
about a publication for a “unique_identifier” from the ESearch result. This information includes all the information about a publication that a user would access in
PubMed. We created another PERL-based XML parser
to extract from the downloaded file: the title of the
paper, the abstract, the first (lead) author name and the
last (presumptive ranking) author, and the journal
name. This information was added to the archive file in
the format: | PubMed links | gene name| drug name |
authors | date of publication | journal name | title of
publication |. This archive file serves as the candidate
article database and a screening tool that is accessed by
the GenDrux web-retrieval system. This archive can be
modified for other diseases by changing the original
search phrase ("breast+cancer+gene+drug”) in E-search.

Interface and system design

The archive file, created as described in the previous
section, was stored on a Windows-based Internet Information Server (IIS) server. It is a single flat file that contains information that will constitute a user’s query. The
Web interface (Figure 1) was created using a PERL program that invoked the CGI.pm module. The module
helps to create web-based query-able interface. The
GenDrux system design is simple. It contains two files:
the Web-retrieval program and the archive file. The system allows users to choose and exclude keywords to
further filter the results. The results are available
instantly and dynamically in the tabulated format.

Results and Discussion
In the creation of the archive file, approximately 8,000
abstracts were downloaded and then reduced to
approximately 4,000 records, using gene name (against
24,000 records) and drug name (~3,050 records) filters.
The number of abstracts in the archival file was reduced
to approximate 4,000. Each record corresponds to a
unique publication. This is not far from the number
that a user browsing through the PubMed web pages
might find, where a “breast cancer AND gene AND

Filtering the archive file for relevance

The archive file containing the abstracts was further processed so each abstract and title contained a valid gene
and drug name associated with breast cancer. We filtered
the archived abstracts and titles only to those that were
listed in the gene annotation files (from human genome
array from Affymetrix, e.g.), NCBI, Ensemble, and GEO
(Gene Expression Omnibus). In addition, we used a compendium of gene synonyms and aliases to improve recall.
In the text of the titles and abstracts, gene names, gene
symbols, aliases, Unigene IDs were all treated as equal.
That is, if the file contained an article to a gene (e.g., Unigene ID), that article was mapped for that record as being
associated with that gene.

Figure 1 The Web interface for the GenDrux system.
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drug” search retrieves a little over 9000 abstracts, a little
over a thousand relevant articles having been added to
PubMed since the archive was created (this will be
updated at regular interval). Our decision to extract
twice in a year from 1975 to 1985, four times a year
between 1986 to 1995 and every month from then on
appears justified.

are precisely named, as opposed to tokens such as parts
of speech, etc. Discussed here are two cases where the
retrieval methodology can be used to extract useful
information and draw conclusions.

Web-based query and visualization procedure

The GenDrux Web portal can be found at http://microarray.uab.edu/drug_gene.pl. The front page of GenDrux
is shown in Figure 1. A user can search the downloaded
literature using one or more parameters: disease, drug
name, and gene name. A negative control feature is also
available, which allows a user to exclude abstracts that
contain specific keywords or phrases. The results
include the title, the abstract, the gene name, drug
name, the date of publication, the name of the first and
ranking author and the journal name, as shown in Figure 2. Each result also includes a link to the PubMed
abstract, as well as link to drug.com and (Gene Ontology) GO website. For academic users or those who subscribe to the journal, this link will also lead the user
(through PubMed) to the full-text of the article. The
system identifies articles that contain references to
genes and drugs for specific cancer. Given the nature of
information retrieval from free-text (this is discussed in
detail later), the system relieves the burdens of processing large amounts of text. We leave it to the clinicianuser to determine the specific relationship or whether
the relationship merits a diagnosis or a prescription.
A user on entering the terms such as “BRCA1” or
“BRCA2” gene names will obtain results, with those
terms highlighted in the title in GenDrux’s results page.
The same applies to the name of a drug. The PERL program looks for exact matches before returning results.
The decision to use exact as opposed to partial matches
is because the names of genes and drugs are tokens that

Figure 2 The searching results by a disease.

User case 1 (Search for a drug name)

Consider a search on the drug “etoposide”. The GenDrux system returns 14 results. Etoposide is a chemotherapeutic drug that is responsible for DNA repair
and has been useful in different forms of cancer. Each
of the results corresponds to a different gene, but the
same drug. This is an interesting observation: in addition to the knowledge desired, i.e., the publications associated for this drug, etoposide is shown to be implicated
in treatments associated with several genes. This is a
possible comment on the ‘one size fits all’ approach to
chemotherapy: different gene expression profiles might
give rise to the same phenotype, and the chemotherapy
modality that uses a specific drug (e.g., etoposide) might
not be beneficial to all.
User Case 2 (Search for disease names)

The archive file was created following a search for articles related to breast cancer. It was further filtered to
abstracts containing the genes and drug names that
have been validated and established by several entities.
A search in GenDrux for “colon cancer” produces 23
results and search for “leukemia” produces 27 results.
On the other hand, a search for “liver cancer” does not
produce any results. Physicians and other users can this
use GenDrux to make assessments related to possible
correlations between the two cancers. At least superficially, there seems to be no correlations between breast
and liver cancers, but there appears to be some between
the two cancers.
The primary purpose of GenDrux is to retrieve relevant gene-drug relationships for specific diseases like
breast cancer, out of the vast biomedical literature. The
tool helps focus the users’ query. It is up to the users, a
physician, e.g., to identify the parameters for correlations
between two types of cancers or the relationship
between a gene that is over or under expressed and a
drug that is used in the treatment of the cancer. A confirmed laboratory-result for a gene may increase confidence for a relevant prescription decision. These
relationships involve expert understanding about very
specific aspects of a domain and cannot be discerned
from this tool. GenDrux, however, retrieves information
in an automated fashion. This saves times and offers a
pool of candidate relationships for users to study and
archive.
This system, developed as a pilot system using breast
cancer as a test-bed, searches, documents, archives, and
updates the gene-drug relations automatically. GenDrux
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relies on a NER scheme, but does not process the natural language of the biomedical text. It does not make
artificial intelligence-type decisions as to the relationship
between a gene profile and its sensitivity to a drug.
When PubMed identifies relevance to a keyword or concept using MeSH (Medical subject heading) term, its
curators do so manually. A more careful perusal of an
article will reveal that the gene name and the drug reference are not in the same sentence or in the same paragraph. The goal of the system, one anticipates, is more
to prevent using medication that implies resistance
when certain gene expression profiles exist, rather than
to suggest a medication that has been implicated sensitive when another gene expression profile exists. GenDrux, as currently developed, relies on the physician
and/or researcher to draw conclusions from the text of
the literature that identifies a gene and a drug, as to the
impact of the drug on the gene, and vice versa. The system, when fully optimized, may incorporate high
throughput gene expression profiles as well as new
drug-related research information to impact the underlying cause for drug sensitivities, and may ultimately
provide physicians with guidelines for prescriptions.
The system provides Web access in a secure way and
is cost effective due to its automated search and retrieval mechanism. The web page contains a link to a survey and a link to the email address of the primary
developer. The latter is to address changes and improvements based on user-requests. Users can seek help and
provide feedbacks in using the system as well as interpreting the results.
One other advantage of this system is that it does not
need downloading and installing software. The system is
platform independence and is scalable. Changing of
search terms from “breast cancer” into other diseases,
during archive file creation, will make the system useful
in that disease domain. The automated download process with the e-search and e-fetch URL embedded in
the Perl wrapper can be used similarly to download
abstracts related to other diseases or research domains.
The system has its limitations as well. Currently, it is
focused on breast cancer. Only the search keywords
(disease name, drug name, etc) in the URL in e-search,
however, need to be changed. Once the abstracts are
downloaded, they can be processed in a text file or a
table in a database. For this prototypical system, given
the sources for gene and drug names, the results are
universally deemed as reliable. Secondly, the system provides a tool of querying candidate gene-drug relations,
which by no means indicate a direct clinical application.
More validation and/or manual annotation and confirmation may be needed for clinical decision support in
personalized breast cancer chemotherapy in the future.

Conclusions
We developed and implemented a prototype system that
searches and archives gene expression and drug sensitivity information. The system is designed to inform a physician such reported gene-drug relationships. The query
results from the system provide physician linkages to
the articles and help them determine their clinical implications. The prototype system that focused on breast
cancer can be extended to other cancer s or non-cancer
diseases.
Availability and requirements
The source code for GenDrux is available for downloading for non-commercial purposes. Please contact
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